Literature DB >> 28194057

Clinical Characteristics and Prognosis of 167 Cases of Acute Erythroleukemia.

Zhi-Qiang Ma1, Ji-Hong Pan2, Da-Xin Jing2, Chong-Yan Xu2.   

Abstract

To observe the biological characteristic and the prognoses in patients with acute erythroleukemia (AEL). The results of 167 patients with newly diagnosed AEL, from January 2004 and June 2014 in the department of Hematology, Shandong Province Chinese Medicine Hospital, were reviewed by morphology, immunology, cytogenetics, molecular biology. Flow cytometry analysis indicated that CD13 (96.1 %), CD33 (95.1 %), CD117 (87.4 %) and CD34 (79.4 %) were highly expressed in AEL. 56 of 148 (37.8 %) AEL patients had a variety of cytogenetic abnormalities, 27 of 148 (18.2 %) patients were complex karyotype (abnormal involving 3 or more chromosomes), the abnormalities of chromosomes 3, 5, 7 and 8 were more frequently involved and the most common one was +8, accounting for 35.7 % of all abnormal karyotype, followed by 5q- (17.9 %). Mutation analysis showed CEBPA mutation ratio of AEL patients was 44.0 % (11/25), that of NPM1as 15.4 % (4/26). Initial induced remission rate of AEL was 56.6 % (30/53), compared by 33.3 % (4/12) of MDSM6. Survival analysis was shown that the overall survival in female was better than that in male (P = 0.047). The overall survival time of transplantation group was significantly longer than chemotherapy group (P = 0.000). The OS of 13-39 years old group was the best, 40-49 years old group took second place, >50 years old group appeared to be the worst. Patients with AML-M6 had dysplasia in varying degrees in granulocyte, erythrocyte and megakaryocyte series. Periodic acid-Shiff reaction staining in polychromatic erythroblast and ortho-chromatic erythroblast had a specificity in the diagnosis of AEL. AEL had its own unique biological features, and allogeneic hematopoietic stem cell transplantation could significantly improve its poor prognosis.

Entities:  

Keywords:  Disease attributes; Erythroblastic, acute; Leukemia; Prognosis

Year:  2016        PMID: 28194057      PMCID: PMC5280856          DOI: 10.1007/s12288-016-0671-1

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  16 in total

1.  Erythroleukaemia in the north of England: a population based study.

Authors:  A W Wells; N Bown; M M Reid; P J Hamilton; G H Jackson; P R Taylor
Journal:  J Clin Pathol       Date:  2001-08       Impact factor: 3.411

2.  Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases.

Authors:  A Kowal-Vern; F M Mazzella; J D Cotelingam; M A Shrit; J T Rector; H R Schumacher
Journal:  Am J Hematol       Date:  2000-09       Impact factor: 10.047

3.  Acute erythroleukemia: evaluation of 48 cases with reference to classification, cell proliferation, cytogenetics, and prognosis.

Authors:  F M Mazzella; A Kowal-Vern; M A Shrit; A L Wibowo; J T Rector; J D Cotelingam; J Collier; A Mikhael; H Cualing; H R Schumacher
Journal:  Am J Clin Pathol       Date:  1998-11       Impact factor: 2.493

4.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

Review 5.  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

Authors:  Francesco Buccisano; Luca Maurillo; Maria Ilaria Del Principe; Giovanni Del Poeta; Giuseppe Sconocchia; Francesco Lo-Coco; William Arcese; Sergio Amadori; Adriano Venditti
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

6.  TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.

Authors:  Wen-Chien Chou; Sheng-Chieh Chou; Chieh-Yu Liu; Chien-Yuan Chen; Hsin-An Hou; Yuan-Yeh Kuo; Ming-Cheng Lee; Bor-Sheng Ko; Jih-Luh Tang; Ming Yao; Woei Tsay; Shang-Ju Wu; Shang-Yi Huang; Szu-Chun Hsu; Yao-Chang Chen; Yi-Chang Chang; Yi-Yi Kuo; Kuan-Ting Kuo; Fen-Yu Lee; Ming-Chi Liu; Chia-Wen Liu; Mei-Hsuan Tseng; Chi-Fei Huang; Hwei-Fang Tien
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

7.  Prognostic factors and treatment effects on survival in acute myeloid leukemia of M6 subtype: a retrospective study of 54 cases.

Authors:  A Colita; A Belhabri; Y Chelghoum; C Charrin; D Fiere; X Thomas
Journal:  Ann Oncol       Date:  2001-04       Impact factor: 32.976

8.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Authors:  Christian Thiede; Sina Koch; Eva Creutzig; Christine Steudel; Thomas Illmer; Markus Schaich; Gerhard Ehninger
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

9.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

10.  Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.

Authors:  F P S Santos; S Faderl; G Garcia-Manero; C Koller; M Beran; S O'Brien; S Pierce; E J Freireich; X Huang; G Borthakur; C Bueso-Ramos; M de Lima; M Keating; J Cortes; H Kantarjian; F Ravandi
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

View more
  1 in total

1.  Functional Evaluation of KEL as an Oncogenic Gene in the Progression of Acute Erythroleukemia.

Authors:  Wenjie Liu; Zijuan Wu; Yan Yu; Chun Qiao; Han Zhu; Ming Hong; Yu Zhu; Sixuan Qian; Suning Chen; Depei Wu; Jianyong Li; Hui Jin
Journal:  Oxid Med Cell Longev       Date:  2022-01-30       Impact factor: 6.543

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.